Dr. Klaus Pollinger and Dr. Martina Breuer, Aenova Group, explore the challenges of development and commercial manufacturing of oral solid dosage forms, from a CDMO perspective.
Two key trends can currently be identified in the pharmaceutical market: innovative drugs are strongly on the rise, and the oral solid dosage form will continue to be the preferred dosage form on the global market.